NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Stock Looks Reasonable On Sales But Stretched After 279% Run
Axsome Therapeutics stock has delivered a strong multi year run, yet the current checks suggest it now looks closer to fairly priced than clearly cheap, leaving investors to weigh recent momentum against a mixed valuation read.
Over the past 5 years, Axsome Therapeutics has returned about 279.2%, which puts recent gains front and center when judging how much upside may be left from here.
The launch of the FOCUS-3 Phase 3 trial for solriamfetol in adolescents with ADHD can support growth...